Xanax alprazolam Withdrawal Symptoms
Xanax alprazolam withdrawal symptoms can vary between individuals, but the normal Xanax alprazolam withdrawal symptoms are increased anxiety, agitation, nervousness, a jittery feeling, being on edge and insomnia.
Below this section of this page, we will give a detailed list of potential Xanax alprazolam side effects, but our mission since 1999 has been to assist people with withdrawal symptoms and to help eliminate the potential withdrawal symptoms. Some people would prefer to remain on Xanax alprazolam, but the side effects are just too much for them. For those people, using our suggestion may very well give you relief from the Xanax alprazolam side effects.
Xanax alprazolam Withdrawal Symptoms Relief
Take 2 nutritional supplements.
Maca Supreme and Optimum Solace are the two supplements.
How you take the supplements will be critical for your success in getting relief from Xanax alprazolam withdrawal symptoms.
You begin by taking Maca Supreme. How you take it is important.
Start with 1 capsule around 8am.
On the 4th day add a second capsule at noon.
Wait 3 more days and then add another capsule at 8am.
Wait 3 more days and add a second capsule at noon.
You will now be taking 2 Maca Supreme at 8am and 2 capsules at noon.
Once you are taking the Maca Supreme as described above, introduce the Optimum Solace.
Take 1 capsule around noon and another capsule around 4pm.
These supplements are available at Neuro Genetic Solutions. Click here for the Maca Supreme and click here for Optimum Solace.
That simple.
You can adjust the supplements around with the time of day you take them, but when first starting the Maca Supreme, take it as described above.
If you find anxiety begins to creep back in in the mid to late afternoon, adjust the Maca Supreme a little. Take the first 2 capsules around 10am and the second 2 capsules around 2pm or 4pm.
It is the same with the Optimum Solace. You can take at different times of the day to match any Xanax alprazolam withdrawal symptoms.
How Fast Will This Work?
The Maca Supreme, once you are taking the full dosage, will generally begin to work around week number 2. For some people it may take 4 weeks for full benefit.
What Do You Do With the Dosage of Xanax alprazolam You Currently Take
Ideally, if you have been reducing the Xanax alprazolam and withdrawal symptoms have started, you will go back up to the last dosage of Xanax alprazolam you were taking when you felt stable.
This may make you feel like you are giving up the ground you have made with reducing Ativan Lorazepam, but in the very short term you will realize you have not only made up the ground you lost, but you are actually successfully getting off the Ativan Lorazepam.
When you restart the Xanax alprazolam withdrawal, reduce the medication by no more than 5 percent of the original dosage by 5 percent.
Xanax alprazolam Withdrawal Symptoms and Side Effects
CARDIAC DISORDERS
Palpitation – Perceptible forcible pulsation of the heart, usually with an increase in frequency or force, with or without irregularity in rhythm.
Tachycardia – Rapid heart rate.
EAR AND LABYRINTH DISORDERS
Ear pain – Any pain connected to the inner or outer portion of the ear.
Tinnitus – A sound in one ear or both ears, such as buzzing, ringing, or whistling, occurring without an external stimulus and usually caused by a separate condition, such as the use of benzodiazepines.
Vertigo – A sensation of irregular or whirling motion, either of oneself or of external objects.
EYE DISORDER
Blurred vision – Compared to normal, a distortion of vision.
Mydriasis – Prolonged abnormal dilation of the pupil of the eye induced by a drug or caused by disease.
Photophobia – An abnormal sensitivity to or intolerance of light, especially by the eyes, as may be caused by eye inflammation. An abnormal fear of light.
GASTROINTESTIONAL DISORDERS
Abdominal pain – Pain between the chest and pelvis, stomach, intestines , liver, spleen, and pancreas.
Constipation – Difficulty having normal bowel movement.
Diarrhea – Excessive and frequent evacuation of watery feces.
Dry mouth – When the mouth is dry beyond what might be normal.
Dyspepsia – Disturbed digestion; indigestion.
Dysphagia – Difficulty in swallowing or inability to swallow.
Nausea – A feeling of sickness with the urge to vomit.
Pharyngolaryngeal syndrome – Of or pertaining to the larynx or pharynx.
Salivary hypersecretion – A continual or excessive amount of saliva that is uncontrollable.
Vomiting – Ejecting all or part of the stomach contents.
GENERAL DISORDERS
Asthenia – Loss or lack of bodily strength.
Chest tightness – A feeling in the chest of contraction.
Edema – An accumulation of an excessive amount of watery fluid in cells, tissues, or body cavities.
Fatigue – The body feeling drained of energy.
Feeling drunk – Feelings associated with drinking too much alcohol.
Feeling hot or cold – An uncontrollable feeling of being too hot or cold that is abnormal for the temperature.
Feeling jittery – An uneasy feeling often associated with the inability to remain still.
Hangover – Feeling like the day after consuming too much alcohol. All or a few hangover sensations may be present.
Increased energy – An abnormal amount of energy bordering on hyper.
Loss of control of legs – Inability to control legs, such as restless leg syndrome.
Malaise – A vague feeling of bodily discomfort, as at the beginning of an illness.
Pyrexia – Fever.
Rigors – Shivering or trembling, as caused by a chill. A state of rigidity in living tissues or organs that prevents response to stimuli.
Sluggishness – A fatigue type feeling or dull.
Thirst – An abnormal sensation of needing liquid.
Weakness – A reduced state of normal energy and stamina.
INFECTIONS AND INFESTATIONS
Influenza symptoms – The body feeling and at times the manifestation of flu like symptoms.
Upper respiratory tract infections – Infection of the nose, sinuses, pharynx (part of neck and throat) or larynx (commonly known as the voice box).
MENTAL DISORDERS
Abnormal dreams – Nightmares or dreams that are upsetting to the individual.
Aggression – Hostile or destructive behavior or actions.
Agitation – A feeling where something or anything could set a person toward anger or combativeness.
Anger – Uncontrollable and volatile emotion with rage; usually an attempt to stop someone or something.
Anxiety – A state of uneasiness and apprehension, as about future uncertainties. A state of intense apprehension, uncertainty, and fear resulting from the anticipation of a threatening event or situation, often to a degree that normal physical and psychological functioning is disrupted.
Apathy – A feeling of no hope, such as if anything can be done it would not work.
Bradyphrenia – A slowness of the mind.
Confusion – An impaired orientation with respect to time, place or the form of an event.
Depersonalization – A state in which the normal sense of personal identity and reality is lost, characterized by feelings that one’s actions and speech cannot be controlled.
Depressed mood – A lowering of the state of mind or emotion compared to what a person normally feels.
Depression – A feeling of no hope.
Derealization – The feeling that things in one’s surroundings are strange, unreal, or somehow altered, as seen in schizophrenia.
Disorientation – A loss of sense of direction, position, or relationship with one’s surroundings. A temporary or permanent state of confusion regarding place, time or personal identity.
Dysphonia – An emotional state marked by anxiety, depression, and restlessness.
Euphoric mood – A feeling of great happiness or well-being, commonly exaggerated and not necessarily well founded.
Hallucination – False or distorted perception of objects or events with a compelling sense of their reality, usually resulting from a traumatic life event or drugs.
Homicidal ideation – The formation of the idea or having the mental image of murder.
Hypomania – A mild form of mania, characterized by hyperactivity and euphoria.
Impulse control – A sudden pushing or driving force. A sudden wish or urge that prompts an unpremeditated act or feeling; an abrupt inclination.
Insomnia – Chronic inability to fall asleep or remain asleep for an adequate length of time.
Irritability – 1. The capacity to respond to stimuli. 2. Abnormal or excessive sensitivity to stimuli of organism, organ, or body part.
Libido decreased – Sexual desire decreased.
Libido increased – Sexual desire increased.
Logorrhea – Incoherent talkativeness.
Mania – A manifestation of bipolar disorder characterized by profuse and rapidly changing ideas, exaggerated gaiety, and excessive physical activity.
Mood swings – The up and or down movement of emotions that are uncontrollable.
Nervousness – Easily agitated or distressed.
Nightmare – A dream creating intense fear, horror, and distress.
Psychomotor retardation – The retardation of movement and or mental process.
Restlessness – An uneasy feeling of not being able to be where one is located comfortably.
Suicidal ideation – The formation of an idea or mental image of killing oneself.
METABOLISM AND NUTRITION DISORDERS
Anorexia – Loss of appetite, usually including a fear of becoming obese or aversion toward food.
Appetite decreased – A decrease in the feeling one needs food for survival.
Appetite increased – An increase of the desire for food for survival.
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS
Arthralgia – Severe pain in a joint.
Back pain – An unexplained pain anywhere in the back.
Muscle cramps – Muscle being contracted to the point of discomfort.
Muscle twitching – A rhythmic or irregular involuntary movement of any muscle.
Myalgia – Muscular pain or tenderness, especially when nonspecific.
Pain in limb – Pain in arm or leg.
NERVOUS SYSTEM DISORDERS
Amnesia – The loss or impairment of memory.
Ataxia – Loss of the ability to coordinate muscular movement.
Coordination abnormal – Maintaining balance of the body difficult in comparison to what is normal for the person.
Disturbance in attention – Not able to remain as focused as one was able to in the past.
Dizziness – A disorienting sensation such as faintness, light-headedness, or unsteadiness.
Dysarthria – Difficulty in articulating words due to emotional stress or to paralysis or incoordination of the muscles used in speaking.
Dyskinesia – An impairment in the ability to control movements, characterized by spasmodic or repetitive motions of lack of coordination.
Headache – A continual or time specific duration with pressure or pain within the head.
Hypersomnia – A condition in which one sleeps for an excessively long time but is normal in the waking intervals.
Hypoesthesia – Drowsiness. Hypotonia – Reduced tension or pressure, as of the intraocular fluid in the eyeball. Relaxation of the arteries.
Memory impairment – Not able to recall an instance from the past as well as before.
Mental impairment – The ability to think and reason diminished.
Paresthesia – A skin sensation, such as burning, prickling, itching, or tingling.
Sedation – An over expression of reduction of anxiety, stress, irritability or excitement.
Seizures – A sudden attack, spasm, or convulsion, as in epilepsy.
Sleep apnea – A temporary cessation of breathing while sleeping.
Sleep talking – Speaking words while asleep.
Somnolence – A state of drowsiness; sleepiness. A condition of semi-consciousness approaching coma.
Stupor – A state of impaired consciousness characterized by a marked diminution in the capacity to react to environmental stimuli.
Syncope – A brief loss of consciousness caused by a sudden fall of blood pressure or failure of cardiac systole, resulting in cerebral anemia.
Tremor – An involuntary trembling movement.
RENAL, THORACIC, AND MEDIASTINAL DISORDERS
Difficulty in micturition – Difficulty with urination or the frequency of.
Urinary frequency – An abnormal frequency of urination.
Urinary incontinence – Involuntary leakage of urine.
REPRODUCTIVE SYSTEM AND BREAST DISORDERS
Dysmenorrhea – A condition marked by painful menstruation.
Premenstrual syndrome – A group of symptoms, including abdominal bloating, breast tenderness, headache, fatigue, irritability, and depression.
Sexual dysfunction – A non-normal, for the individual, behavior or ability to have sex.
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS
Choking sensation – A feeling of choking with or without cause.
Dyspnea – Difficulty in breathing, often associated with lung or heart disease and resulting in shortness of breath.
Epistaxis – Nosebleed.
Hyperventilation – Abnormally fast or deep respiration resulting in the loss of carbon dioxide from the blood, thereby causing a decrease in blood pressure and sometimes fainting.
Nasal congestion – A stoppage or restriction of the nasal passage.
Rhinitis – Inflammation of the nasal membranes.
Rhinorrhea – A discharge from the mucous membrane, especially if excessive.
VASCULAR DISORDERS
Hot flashes – A sudden, brief sensation of heat, often over the entire body, caused by a transient dilation of blood vessels of the skin.
Hypotension – Abnormally low arterial blood pressure.
SKIN AND SUBCUTANEOUS TISSUE DISORDERS
Clamminess – Abnormally moist, sticky and cold to the touch.
Pruritus – Severe itching, often of undamaged skin.
Rash – A skin eruption. Sweating increased – Abnormal increase of perspiration.
Urticaria – A skin condition characterized by welts that itch intensely, caused by an allergic reaction, an infection, or nervous condition.
1. FDA drug label Xanax (alprazolam tablets) Revised 2016 [cited 2023 May 24]
2. Ashton H. The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry. 2005 May;18(3):249-55. doi: 10.1097/01.yco.0000165594.60434.84. PMID:16639148. [cited 2023 May 24]
3. Connecticut Gvt. Department of Consumer Protection Information “Aprazolam” [cited 2023 May 24]
4. FDA information, “Finding and Learning About Side Effects (adverse reactions).” 2018 July 19 [cited 2023 May 24]
5. DailyMed prescription drug information, “Alprazolam” NIH publication Mar 21, 2021 [cited 2023 May 24]
6. Ashton H, “Benzodiazepines – How they Work and How to Withdraw” aka “The Ashton Manual” [revised Aug 2002] [cited 2023 May 24]
7. Garzone PD, Kroboth PD. Pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet. 1989 Jun;16(6):337-64. doi: 10.2165/00003088-198916060-00002. PMID: 2567646. [cited 2023 May 24]
8. Browne JL, Hauge KJ. A review of alprazolam withdrawal. Drug Intell Clin Pharm. 1986 Nov;20(11):837-41. doi: 10.1177/106002808602001102. PMID: 3536383.[cited 2023 May 24]
9. Bosshart H. Withdrawal-induced delirium associated with a benzodiazepine switch: a case report. J Med Case Rep. 2011 May 26;5:207. doi: 10.1186/1752-1947-5-207. PMID: 21615891; PMCID: PMC3117827. [cited 2023 May 24]
10. Busto U, Sellers EM, Naranjo CA, Cappell H, Sanchez-Craig M, Sykora K. Withdrawal reaction after long-term therapeutic use of benzodiazepines. N Engl J Med. 1986 Oct 2;315(14):854-9. doi: 10.1056/NEJM198610023151403. PMID: 3092053. [cited 2023 May 24]
11. O’brien CP. Benzodiazepine use, abuse, and dependence. J Clin Psychiatry. 2005;66 Suppl 2:28-33. PMID: 15762817. [cited 2023 May 24]
12. Kang M, Galuska MA, Ghassemzadeh S. Benzodiazepine Toxicity. [Updated 2021 Jul 1]. In: StatPearls Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482238/ [cited 2023 May 24]
13. Ananth J. Benzodiazepines: selective use to avoid addiction. Postgrad Med. 1982 Oct;72(4):271-6. doi: 10.1080/00325481.1982.11716231. PMID: 6126869. [cited 2023 May 24]
14. Schmitz A. Benzodiazepine use, misuse, and abuse: A review. Ment Health Clin. 2016;6(3):120-126. Published 2016 May 6. doi:10.9740/mhc.2016.05.120 [cited 2023 May 24]
15. Temte V, Kjeldstadli K, Bruun LD, Birdal M, Bachs L, Karinen R, Middelkoop G, Øiestad E, Høiseth G. An Experimental Study of Diazepam and Alprazolam Kinetics in Urine and Oral Fluid Following Single Oral Doses. J Anal Toxicol. 2019 Mar 1;43(2):104-111. doi: 10.1093/jat/bky062. PMID: 30517712. [cited 2023 May 24]
16. Santo L, Rui P, Ashman J, “Physician Office Visits at which Benzodiazepines were Prescribed: Findings from 2014-2016 National Ambulatory Medical Care Survey” CDC national Health Statistics Reports #137 January 17,2020 [cited 2023 May 24]
17. Otte C. Cognitive behavioral therapy in anxiety disorders: current state of the evidence. Dialogues Clin Neurosci. 2011;13(4):413-421. doi:10.31887/DCNS.2011.13.4/cotte [cited 2023 May 24]
18. DeRubeis RJ, Siegle GJ, Hollon SD. Cognitive therapy versus medication for depression: treatment outcomes and neural mechanisms. Nat Rev Neurosci. 2008;9(10):788-796. doi:10.1038/nrn2345 [cited 2023 May 24]
19. Otto MW, McHugh RK, Simon NM, Farach FJ, Worthington JJ, Pollack MH. Efficacy of CBT for benzodiazepine discontinuation in patients with panic disorder: Further evaluation. Behav Res Ther. 2010 Aug;48(8):720-7. doi: 10.1016/j.brat.2010.04.002. Epub 2010 Apr 28. PMID: 20546699; PMCID: PMC5962448. [cited 2023 May 24]
20. He Q, Chen X, Wu T, Li L, Fei X. Risk of Dementia in Long-Term Benzodiazepine Users: Evidence from a Meta-Analysis of Observational Studies. J Clin Neurol. 2019;15(1):9-19. doi:10.3988/jcn.2019.15.1.9 [cited 2023 May 24]
21. Statistical Report “The Top 300 of 2021” published online by Clincalc Database [cited 2023 May 24]
22. CDC statistics report published August 2021, Fatal and Nonfatal Overdoses Benzodiazepines [cited 2023 May 24]
23. Genuis SJ. Toxic causes of mental illness are overlooked. Neurotoxicology. 2008 Nov;29(6):1147-9. doi: 10.1016/j.neuro.2008.06.005. Epub 2008 Jun 24. PMID: 18621076. [cited 2023 May 24]
24. Swedish Council on Health Technology Assessment. Treatment of Anxiety Disorders: A Systematic Review Stockholm: Swedish Council on Health Technology Assessment (SBU); 2005 Nov. SBU Yellow Report No. 171/1+2. PMID: 28876726. [cited 2023 May 24]
25. Ait-Daoud N, Hamby AS, Sharma S, Blevins D. A Review of Alprazolam Use, Misuse, and Withdrawal. J A Med. 2018;12(1):4-10. doi:10.1097/ADM.0000000000000350 [cited 2023 May 24]
26. Pecknold JC, Swinson RP, Kuch K, Lewis CP. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. III. Discontinuation effects. Arch Gen Psychiatry. 1988 May;45(5):429-36. doi: 10.1001/archpsyc.1988.01800290043006. PMID: 3282479. [cited 2023 May 24]
27. Fyer AJ, Liebowitz MR, Gorman JM, Campeas R, Levin A, Davies SO, Goetz D, Klein DF. Discontinuation of alprazolam treatment in panic patients. Am J Psychiatry. 1987 Mar;144(3):303-8. doi: 10.1176/ajp.144.3.303. PMID: 3826428. [cited 2023 May 24]
28. Laegreid L, Olegård R, Walström J, Conradi N. Teratogenic effects of benzodiazepine use during pregnancy. J Pediatr. 1989 Jan;114(1):126-31. doi: 10.1016/s0022-3476(89)80619-5. PMID: 2562851.[cited 2023 May 24]
29. Risse SC, Whitters A, Burke J, Chen S, Scurfield RM, Raskind MA. Severe withdrawal symptoms after discontinuation of alprazolam in eight patients with combat-induced posttraumatic stress disorder. J Clin Psychiatry. 1990 May;51(5):206-9. PMID: 2335496. [cited 2023 May 24]
30. Pétursson H. The benzodiazepine withdrawal syndrome. Add. 1994 Nov;89(11):1455-9. doi: 10.1111/j.1360-0443.1994.tb03743.x. PMID: 7841856. [cited 2023 May 24]
31. Goffinet S. Mécanisme d’action, indications et abus des benzodiazépines anxiolytiques [Mechanism of action, indications and abuse of benzodiazepine anxiolytic drugs]. Ann Med Psychol (Paris). 1993 Jan;151(1):47-63. French. PMID: 7905724. [cited 2023 May 24]
32. Lader M. Long-term anxiolytic therapy: the issue of drug withdrawal. J Clin Psychiatry. 1987 Dec;48 Suppl:12-6. PMID: 2891684. [cited 2023 May 24]
33. Peart R, Toxicity, Cognitive Impairment, Long Term Damage, and The Post Withdrawal Syndrome [published online December 2000] [cited 2023 May 24]
34. Perlis RH. Misdiagnosis of bipolar disorder. Am J Manag Care. 2005 Oct;11(9 Suppl):S271-4. PMID: 16232009.[cited 2023 May 24]
35. Boyadzhieva A, Kayhan E. Keeping the Breath in Mind: Respiration, Neural Oscillations, and the Free Energy Principle. Front Neurosci. 2021 Jun 29;15:647579. doi: 10.3389/fnins.2021.647579. PMID: 34267621; PMCID: PMC8275985. [cited 2023 May 24]
36. Saeed SA, Cunningham K, Bloch RM. Depression and Anxiety Disorders: Benefits of Exercise, Yoga, and Meditation. Am Fam Physician. 2019 May 15;99(10):620-627. PMID: 31083878. [cited 2023 May 24]
37. Shah NA, Abate MA, Smith MJ, Kaplan JA, Kraner JC, Clay DJ. Characteristics of alprazolam-related deaths compiled by a centralized state medical examiner. Am J Addict. 2012 Nov;21 Suppl 1:S27-34. doi: 10.1111/j.1521-0391.2012.00298.x. PMID: 23786507.[cited 2023 May 24]